Trial Profile
Phase III Study of Atamestane Plus Toremifene in Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Atamestane (Primary) ; Toremifene
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Intarcia Therapeutics
- 14 Jun 2008 Status changed from in progress to discontinued, as reported by ClinicalTrials.gov.
- 09 Sep 2005 New trial record.